Aurore Vozy
YOU?
Author Swipe
View article: Vinorelbine With or Without Thiotepa for <scp>HER2</scp>‐Negative Metastatic Breast Cancer: A Propensity Score Analysis
Vinorelbine With or Without Thiotepa for <span>HER2</span>‐Negative Metastatic Breast Cancer: A Propensity Score Analysis Open
Background Vinorelbine is commonly used to treat metastatic breast cancer (mBC), while thiotepa is known for its ability to cross the blood–brain barrier. Methods Our retrospective study aimed to compare the efficacy and safety of vinorelb…
View article: Prognosis and Phenotypes of Advanced Head and Neck Carcinoma Associated With Hypercalcemia
Prognosis and Phenotypes of Advanced Head and Neck Carcinoma Associated With Hypercalcemia Open
Purpose Hypercalcemia is the most common metabolic disorder in cancer, affecting 10%–20% of patients with advanced malignancies, including squamous cell carcinoma of the head and neck (HNSCC), though its prognostic significance remains poo…
View article: Burden of grade 3 or 4 liver injury associated with immune checkpoint inhibitors
Burden of grade 3 or 4 liver injury associated with immune checkpoint inhibitors Open
View article: FOLFIRI in advanced platinum-resistant/refractory small-cell lung cancer: a retrospective study
FOLFIRI in advanced platinum-resistant/refractory small-cell lung cancer: a retrospective study Open
FOLFIRI showed some activity for platinum-resistant/refractory SCLC in terms of overall response and had an acceptable safety profile. However, caution is needed in interpreting this result. FOLFIRI could represent a potential new treatmen…
View article: Cytochrome P-450-mediated herb and food–drug interactions can be identified in cancer patients through patient self-reporting with a tablet application: results of a prospective observational study
Cytochrome P-450-mediated herb and food–drug interactions can be identified in cancer patients through patient self-reporting with a tablet application: results of a prospective observational study Open
Self-assessment of HFDS interaction with cancer treatment with an application is feasible and should be considered in daily routine. Prospective interventional studies should be conducted to better assess the clinical benefits of this appr…
View article: Reversible Tumor Progression Induced by a Dexamethasone Course for Severe COVID-19 during Immune Checkpoint Inhibitor Treatment
Reversible Tumor Progression Induced by a Dexamethasone Course for Severe COVID-19 during Immune Checkpoint Inhibitor Treatment Open
Immunotherapies and immune checkpoint inhibitors (ICI) represent the latest revolution in oncology. Several studies have reported an association between the use of corticosteroids and poorer outcomes for patients treated with ICIs. However…
View article: High seroconversion rate but low antibody titers after two injections of BNT162b2 (Pfizer-BioNTech) vaccine in patients treated with chemotherapy for solid cancers
High seroconversion rate but low antibody titers after two injections of BNT162b2 (Pfizer-BioNTech) vaccine in patients treated with chemotherapy for solid cancers Open
View article: Weak immunogenicity after a single dose of SARS-CoV-2 mRNA vaccine in treated cancer patients
Weak immunogenicity after a single dose of SARS-CoV-2 mRNA vaccine in treated cancer patients Open
View article: Comparaison des caractéristiques et des pronostics des patients avec et sans cancer actif hospitalisés pour une infection à SARS-CoV-2
Comparaison des caractéristiques et des pronostics des patients avec et sans cancer actif hospitalisés pour une infection à SARS-CoV-2 Open
View article: Cardiotoxicity Associated with Gemcitabine: Literature Review and a Pharmacovigilance Study
Cardiotoxicity Associated with Gemcitabine: Literature Review and a Pharmacovigilance Study Open
Background: Gemcitabine is a nucleoside analog, widely used either alone or in combination, for the treatment of multiple cancers. However, gemcitabine may also be associated with cardiovascular adverse-drug-reactions (CV-ADR). Methods: Fi…
View article: Clinical Pharmacology and Interplay of Immune Checkpoint Agents: A Yin-Yang Balance
Clinical Pharmacology and Interplay of Immune Checkpoint Agents: A Yin-Yang Balance Open
T cells have a central role in immune system balance. When activated, they may lead to autoimmune diseases. When too anergic, they contribute to infection spread and cancer proliferation. Immune checkpoint proteins regulate T cell function…
View article: Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer
Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer Open
View article: Metadata and data associated with the published article: Systemic Short Chain Fatty Acids limit antitumor effect of CTLA-4 blockade in hosts with cancer
Metadata and data associated with the published article: Systemic Short Chain Fatty Acids limit antitumor effect of CTLA-4 blockade in hosts with cancer Open
This dataset consists of 10 .xlsx spreadsheets containing all source data from the related manuscript. The spreadsheets are as follows.- NCOMMS-19-10571A_Raw NGS data.xlsx This spreadsheet contains summary statistics for all …
View article: Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer
Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer Open
The risk-reward ratio for an anti-PD-1 or anti-PD-L1 rechallenge appears to be acceptable, although these patients require close monitoring; further investigation into rechallenge conditions through a prospective clinical trial is needed.
View article: Safety assessment of anti-PD(L)1 rechallenge after immune-related adverse events
Safety assessment of anti-PD(L)1 rechallenge after immune-related adverse events Open
Background: Immune checkpoint inhibitors (ICI) have demonstrated efficacy in many cancers. Patients can experience immune-related adverse events (irAE) and their management become crucial. Evidence-based guidance regarding the safety of re…
View article: Inclusion of adolescents in adult early phase trials and young adults in paediatric early phase trials: A reality or a myth?
Inclusion of adolescents in adult early phase trials and young adults in paediatric early phase trials: A reality or a myth? Open